Table 5.
Clinical trials of mRNA encoding Ab.
| Period | Product | Type | Study | Phase | Sponsor | Formulation | Route | Other Therapy | Response |
|---|---|---|---|---|---|---|---|---|---|
| 2020–2024 | BNT141 (mRNA encoding anti-Claudin18.2 monoclonal antibody) | unresectable or metastatic CLDN18.2-positive gastric, pancreatic, ovarian, and biliary tract tumors | NCT04683939 | Phase I/II | BioNTech SE | LNP | i.v. | nab-paclitaxel, gemcitabine | ongoing |
| 2022–2026 | BNT142 (mRNA encoding antibodies targeting CD3 × CLDN6) | solid tumor | NCT05262530 | Phase I/II | BioNTech SE | LNP | i.v. | / | ongoing |
Abbreviations: i.v., intravenous injection; LNP, lipid nanoparticle; CLDN18.2, claudin 18.2; CLDN6, the tight-junction protein claudin 6.